沃生物制药
VOR
18.03
-1.31
-6.77%
沃生物制药
US · VOR
#3175 按市值排名
上市于 2021
18.03
-1.31
-6.77%
实时 - 追踪5344个代码 - 心跳于203秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了2家。
- 机构持股总比例下降了0.9个百分点。
机构持股
- 机构持股比例
- 98.32% -0.91pp
- 机构数量
- 129 +2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund46.81%
Mutual Fund31.91%
Hedge Fund18.19%
Individual/Insider2.00%
Public Company1.03%
Private Company0.20%
Insurance Company0.14%
主要股东 截至 2026-07-31
FMR
11.00% · 6.51M 股
TCG Crossover Management, LLC
9.59% · 5.67M 股
RA Capital Management, L.P.
7.61% · 4.50M 股
Forbion Capital Partners B.V.
6.96% · 4.12M 股
BlackRock
5.86% · 3.47M 股
VERVE CAPITAL, Inc.
5.77% · 3.41M 股
VR Management, LLC
5.14% · 3.04M 股
State Street Global Advisors
4.42% · 2.62M 股
Frazier Life Sciences Management, LP
4.30% · 2.54M 股
Vanguard Capital Management, LLC
4.03% · 2.39M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 19次买入 · 28次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Reid Hoffman | -- | 1.97% |
| Robert Ang | Chief Executive Officer | 0.01% |
| Tirtha Chakraborty | Chief Scientific Officer | 0.01% |
| Matthew Patterson | Independent Chairperson | 0.00% |
| Sven Lundberg | Independent Director | 0.00% |
| Han Choi | Chief Financial Officer | 0.00% |
| Eyal Attar | Chief Medical Officer | 0.00% |
| David Lubner | Independent Director | -- |
| Sarah Watt Reed | Independent Director | -- |
| RA Capital Management, L.P. | -- | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-10-01 | RA Capital Management, L.P. | -- | Derivative Exercise and Retained | +500 | $12.80 |
| 2026-08-23 | RA Capital Management, L.P. | -- | Derivative Exercise and Retained | +1,500 | $3.74 |
| 2026-07-15 | RA Capital Management, L.P. | -- | Derivative Exercise and Sale | -213 | $0.00–19.75 |
| 2026-07-15 | RA Capital Management, L.P. | -- | Derivative Exercise and Retained | +2,099,787 | $0.00 |
| 2026-07-06 | David Zaccardelli | Director | Other Derivative Acquisition | +42,658 | $20.10 |
| 2026-06-10 | RA Capital Management, L.P. | -- | Other Derivative Acquisition | +57,162 | $14.09 |
| 2026-06-10 | Michel Detheux | Director | Other Derivative Acquisition | +57,162 | $14.09 |
| 2026-06-10 | Sabretooth Capital Management, LLC | -- | Other Derivative Acquisition | +57,162 | $14.09 |
| 2026-06-10 | Daniella Beckman | Independent Director | Other Derivative Acquisition | +53,283 | $14.09 |
| 2026-06-10 | Andrew Levin | Director | Other Derivative Acquisition | +57,162 | $14.09 |
| 2026-06-10 | Alexander Cumbo | Director | Other Derivative Acquisition | +56,345 | $14.09 |
| 2026-06-10 | Fouad Namouni | Director | Other Derivative Acquisition | +56,549 | $14.09 |
| 2026-06-10 | Wouter Sebastian Joustra | Director | Other Derivative Acquisition | +57,162 | $14.09 |
| 2026-04-21 | RA Capital Management, L.P. | -- | Open Market Disposition | -165,150 | $15.77 |
| 2026-04-19 | RA Capital Management, L.P. | -- | Open Market Disposition | -630,374 | $15.77–16.28 |
| 2026-04-14 | RA Capital Management, L.P. | -- | Open Market Disposition | -737,989 | $15.97–16.15 |
| 2026-04-09 | RA Capital Management, L.P. | -- | Open Market Disposition | -484,932 | $15.75–16.91 |
| 2026-04-08 | RA Capital Management, L.P. | -- | Private Disposition | -135,201 | $16.59 |
| 2026-04-05 | RA Capital Management, L.P. | -- | Open Market Disposition | -849,257 | $16.51–19.06 |
| 2026-03-31 | Jeremy Sokolove | Chief Medical Officer | Initial Statement of Beneficial | 0 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
沃生物制药 讨论区 0 条评论